Pathology: mGC or mGEJC - L2 - all population; mGC or mGEJC - L2 - PDL1 positive;
| mGC or mGEJC - L2 - all population | mGC or mGEJC - L2 - PDL1 positive | |||||
| JAVELIN Gastric 300, 2018 | CA184-162, 2017 | ATTRACTION-2 (Kang), 2017 | KEYNOTE-061 (all population), 2018 | KEYNOTE-061 (PDL1 CPS>1), 2018 | ||
| pembrolizumab alone | 2 | T1 | T1 | |||
| avelumab alone | 1 | T1 | ||||
| Ipilimumab (10 mg/kg) | 1 | T1 | ||||
| nivolumab alone | 1 | T1 | ||||
| paclitaxel | 0 | T0 | T0 | |||
| Standard of Care (SoC) | 0 | T0 | T0 | |||
| placebo | 0 | T0 | ||||